Novartis AG (DE:NOT)
XETRA:NOT
NOT Stock Chart & Stats
€129.50
€0.00(0.00%)
At close: 4:00 PM EST
€129.50
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€79.74 - €144.12
Previous CloseN/A
Volume24.84K
Average Volume (3M)909.00
Market Cap
€239.67B
Enterprise Value€317.62B
Total Cash (Recent Filing)€11.58B
Total Debt (Recent Filing)€37.01B
Price to Earnings (P/E)18.3
Beta0.44
Next Earnings
Apr 28, 2026EPS Estimate
1.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.74
Shares Outstanding2,034,819,500
10 Day Avg. Volume1,167
30 Day Avg. Volume909
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)5.81
Price to Sales (P/S)4.69
P/FCF Ratio14.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€133.31Price Target Upside2.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)9.51
Revenue Forecast (FY)€62.22B
Bulls Say, Bears Say
Bulls Say
Commercial MomentumStrong prescription trends for several recently launched therapies underpin revenue growth prospects and may support sustained sales momentum as core products face lifecycle pressures.
Late-stage PipelineMultiple late-stage trial readouts from diversified pipeline assets could materially improve growth prospects and help offset revenue declines from expiring products, supporting analyst optimism.
Strategic AcquisitionAvidity acquisition adds two late-stage drug candidates that could materially expand future revenue potential and attract partnership or acquisition interest.
Bears Say
BTK Development And Safety RiskRemibrutinib faces development risk due to absence of intermediate multiple sclerosis data, questions about brain penetration and potency, and potential liver monitoring requirements that could limit clinical uptake.
Generic ErosionErosion from generic competition on several legacy medicines is reducing sales and compressing margins, increasing pressure on core profitability.
Pelacarsen Clinical Adoption RiskUncertainty about whether Lp(a) lowering will translate into meaningful cardiovascular risk reduction, combined with competitors showing stronger biomarker reductions, creates adoption and differentiation risk for pelacarsen.
Novartis AG News
NOT FAQ
What was Novartis AG’s price range in the past 12 months?
Novartis AG lowest stock price was €79.74 and its highest was €144.12 in the past 12 months.
What is Novartis AG’s market cap?
Novartis AG’s market cap is €239.67B.
When is Novartis AG’s upcoming earnings report date?
Novartis AG’s upcoming earnings report date is Apr 28, 2026 which is in 19 days.
How were Novartis AG’s earnings last quarter?
Novartis AG released its earnings results on Feb 04, 2026. The company reported €1.741 earnings per share for the quarter, beating the consensus estimate of €1.705 by €0.035.
Is Novartis AG overvalued?
According to Wall Street analysts Novartis AG’s price is currently Undervalued.
Does Novartis AG pay dividends?
Novartis AG does not currently pay dividends.
What is Novartis AG’s EPS estimate?
Novartis AG’s EPS estimate is 1.81.
How many shares outstanding does Novartis AG have?
Novartis AG has 2,034,819,500 shares outstanding.
What happened to Novartis AG’s price movement after its last earnings report?
Novartis AG reported an EPS of €1.741 in its last earnings report, beating expectations of €1.705. Following the earnings report the stock price went up 1.336%.
Which hedge fund is a major shareholder of Novartis AG?
Currently, no hedge funds are holding shares in DE:NOT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
NOT Stock 12 Month Forecast
Average Price Target
€133.31
▲(2.94% Upside)
Technical Analysis
Options Prices
Currently, No data available
---